Skip to contentA
Autolus Therapeutics plc
A
AUTLAutolus Therapeutics plc Q1 2025 · 10-Q
Revenue$8.98M$8.98M−11.0% vs Q1 2024 Net Income-$70.16M-$70.16MN/M vs Q1 2024 EPS Diluted-$0.26-$0.26N/M vs Q1 2024 Operating Income-$65,240,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Autolus Therapeutics plc · CIK 1730463 · Engraved from SEC EDGAR
Free Cash Flowderived-$83,808,000N/M Margins · derivedOperating margin-726.3%−342.3 pt vs Q1 2024
Net margin-781.1%−259.0 pt vs Q1 2024
ended Mar 31, 2025 · filed May 8, 2025 · 38 d after period end